Personalised Cancer Therapeutics
Mass in vivo analysis
Personal Discovery ProcessTM
replicates a patient’s genetic profile and screens thousands of drug cocktails
The Icahn School of Medicine at Mount Sinai developed the PDP methodology over years of clinical research. They found that real-world patient tumours are made resistant to single-drug treatments by mutations in several genes, including genes not previously associated with cancer. Such resistant tumours can however, be effectively addressed with novel combinations of FDA approved drugs. The most effective combinations almost always include non-cancer drugs. The Personal Discovery Process methods are licensed exclusively to My Personal Therapeutics (trading as Vivan Therapeutics).